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High levels of BAALC, ERG, EVI1 and MN1 expression have been associated with shorter overall survival in AML but
standardized and clinically validated assays are lacking. We have therefore developed and optimized an assay for
standardized detection of these prognostic genes for patients with intermediate cytogenetic risk AML. In a training
set of 147 intermediate cytogenetic risk cases we performed cross validations at 5 percentile steps of expression
level and observed a bimodal significance profile for BAALC expression level and unimodal significance profiles for
ERG and MN1 levels with no statistically significant cutoff points near the median expression level of BAALC, ERG or
MN1. Of the possible cutoff points for expression levels of BAALC, ERG and MN1, just the 30th and 75th percentile of
BAALC expression level and the 30th percentile of MN1 expression level cutoff points showed clinical significance.
Of these only the 30th percentile of BAALC expression level reproduced in an independent verification (extended
training) data set of 242 cytogenetically normal AML cases and successfully validated in an external cohort of 215
intermediate cytogenetic risk AML cases. Finally, we show independent prognostic value for high EVI1 and low
BAALC in multivariate analysis with other clinically relevant molecular AML markers. We have developed a highly
standardized molecular assay for the independent gene expression markers EVI1 and BAALC.
Keywords: AML, Acute myeloid leukemia, BAALC, Brain and acute leukemia cytoplasmic, EVI1, Ecotropic viral
integration site 1, Intermediate cytogenetic risk, Prognosis, OS, Overall survivalBackground
Overexpressions of EVI1, BAALC, ERG, and MN1 have
been reported to be prognostically relevant in AML [1-9].
For instance, the prognostic value of EVI1 overexpression
was discovered and reproduced in intermediate cytogen-
etic risk AML [4,9-13], while the prognostic value of
BAALC, ERG and MN1 mRNA values were demonstrated
in normal karyotype AML [1,6,8]. These studies selected
univariate cutoff points for BAALC, ERG, and MN1 con-
tinuous expression levels based on cohort quartiles, while
the EVI1 expression cutoff point was chosen to discrimin-
ate between undetectable or low levels versus high expres-
sion levels. Translation to the clinic has been proposed
[14-20] but lack of standardized assays has hampered their* Correspondence: e.vanbeers@skyline-diagnostics.com
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reproduction in any medium, provided the orbroad implementation. We have developed a prognostic
assay on a custom gene expression array that detects EVI1
overexpression and low BAALC expression levels in indi-
vidual AML patients as part of a multiplex genetic array
that also detects AML with t(8;21), t(15;17), inv(16)/t
(16;16), NPM1 mutations, and CEBPA double mutations
with high accuracy (sensitivity and specificity > 95%).Results and discussion
OS prognostic assay for BAALC, ERG, and MN1
BAALC, ERG and MN1 gene expression levels were de-
termined in a standardized assay suitable for single case
analysis (see Methods) in a training set, an independent
verification (extended training) set and one independent
validation set of AML patients. Distributions of ERG
mRNA levels on average were higher in the training co-
hort as compared with the verification cohort (Figure 1A)
while MN1 and BAALC expression levels were similartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Expression distribution for ERG, MN1 and BAALC in intermediate cytogenetic risk AML. Figure A-C; x-axes shows cases sorted by
expression in training (red) or verification (green) cohorts, while the y-axis shows standardized expression values. Figure D-F; x axis shows all
seventeen 5-percentile intervals between 10 and 90. The y-axis indicates the significant fraction (%) of 1000 folds cross-validation draws in the
training cohort (red bars) or verification cohort (green bars) for ERG, MN1 and BAALC, respectively. Significance is defined by log rank p-value < 0.05.
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(CV) in the training and verification cohorts for BAALC,
ERG, and MN1 expression levels (Figure 1D-F). For
BAALC expression levels there are two local optima in
the training cohort at the 30th percentile cutoff point
and 75th percentile cutoff points with 23% and 47% sig-
nificant folds (y-axis) with a log rank for OS p < 0.05. At
the 25th, 30th and 35th percentile there are 10%, 9% and
23% of the 1000 random cohort splits in the validation
cohort (Figure 1D, green bars). Clearly only the 30th per-
centile BAALC cutoff point is supported by the verifica-
tion cohort and thus chosen for lock-down and further
validation.
No significant cutoff point for ERG expression levels
were found in the training cohort at any of 17 expression
cutoff points analyzed (Figure 1E), because the percentage
(y-axis in Figure 1E) of the 1000 random cohort splits was
< 1% for every cutoff point. Therefore, due to ambiguous
training and verification results, ERG expression levels
were not considered for validation. For MN1 mRNA ex-
pression levels (Figure 1F) there is an optimum at the 30th
percentile in the training cohort corresponding with a
normalized expression value −0.76 and achieving 51%significant cross validation splits. Although, this cutoff
point could not be reproduced in the independent verifica-
tion cohort, it was assessed for further validation on an in-
dependent cohort. The prognostic value of both ERG and
MN1 expression levels for overall survival is inconsistent
between training and verification cohorts (Figure 1).
Finding a clinically relevant cutoff point for EVI1
expression
The distribution of EVI1 mRNA expression levels in the
training cohort is extremely skewed as can be seen in
Figure 2A. Figure 2A also shows the cutoff point of
0.987, which was derived by maximizing the logrank test
statistic (see Statistical analysis). All cases with a high
EVI1 expression level (above the cutoff point) have a
short survival and died (Figure 2B, red circle) while the
cases with a low EVI1 expression level (below the cutoff
point) have much longer survival.
Cutoff point validation
The prognostic significance for OS between BAALC low-
expressers and high-expressers in the training (left) cohort
and validation (right) cohort (Table 1 and Figure 3) (HR
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Figure 2 Plot of EVI1 expression versus the percentile of EVI1 (A) and of EVI1 gene expression versus overall survival (OS) in months
(B) both for the training cohort.
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low EVI1 expression (HR 0.442, p-val .012 and HR 0.44,
p-val .004) and therefore both pass the validation. How-
ever, MN1 gene expression levels is only statistically sig-
nificant for the training cohort (HR 0.456, p-val 0.00045)
but not for the validation cohort (HR 0.877, p-val 0.2329)
and thus will not be considered further. Since for ERG ex-
pression levels no significant cutoff point was identified in
the training cohort (Figure 1) it was not included in the
validation study.
Cutoff point in relation to event free survival
Low BAALC and high EVI1 were also prognostic for EFS
in the training and validation cohorts BAALC (training
p = 0.0038; validation p = 0.0105 by the logrank test) and
EVI1 (training p = 0.0164; validation p = 0.00125 by the
logrank test), respectively.
NPM1, CEBPA and FLT3 mutation frequencies in BAALC,
EVI1 expression subgroups
We examined the distribution of AML mutations
NPM1, CEBPAdm and FLT3-ITD among low BAALCTable 1 Hazard ratio and logrank (p-value) for evaluated cut
Gene name Dataset AMLprofiler
BAALC Training .48 (.001)
Verification *) .60 (.002)
Validation .69 (.021)
ERG Training No significant cutoff point
Verification *) ND
Validation ND
MN1 Training 2.19 (< .001)
Verification *) 1.31 (.049)
Validation 1.14 (.2329)
OS logrank p < 0.05 indicated in bold. For ERG no cut point was identified in the tra
*) this data set contains only normal karyotype cases.
ND, not done because lack of significant cutoff point in training.and high EVI1 expression AML, respectively (Tables 2
and 3). Low BAALC expression cases had significantly
more NPM1 mutations (49/85) compared with high
BAALC expressors (36/85) (Fisher’s exact, p < 0.0001).
All 10 CEBPA double mutants were present in high
BAALC expressors and therefore significantly enriched
(Fisher’s exact, p = 0.0146). FLT3-ITD mutant frequency
did not differ between low (25/81) or high (54/134)
BAALC expressors (Fisher’s exact, p = 0.148).
NPM1 mutations were enriched (85/203) in low EVI1
compared with none in 12 high EVI1 (Table 3, p = 0.0039).
CEBPA double mutant frequency did not differ between
low EVI1 expressors (10/203) or high EVI1 expressors
(0/12) (Fisher’s exact, p = 1). And finally, FLT3 mutation
frequency did not significantly differ between low and
high EVI1 expressors (Table 3, p = 0.218).
Multivariate analysis
The prognostic value of BAALC and EVI1 expression levels
was further tested in a multivariate Cox-Proportional Haz-
ard analysis in the validation cohort adjusting for potential
confounding covariates including the mutation markerspoints in training, verification and validation datasets
25th percentile 50th percentile 75th percentile
.44 (< .001) .63 (.01) .43(< .001)
.55 (.001) .66(.005) .65 (.007)
.72 (.066) .88 (.24) .93 (.345)
1.41 (.066) 1.37 (.051) 1.45 (.048)
1.41 (.037) 1.56 (.003) 1.72 (.001)
1.54 (.02) 1.12 (.248) 1.28 (.099)
2.56 (< .001) 1.79 (.002) 1.79 (.003)
1.12 (.26) 1.32 (.049) 1.39 (.035)
1.37 (.068) 1.19 (.167) 1.32 (.081)
ining cohort.





























BAALC: Training Cohort: (n = 147)
p−value (log−rank one sided) = 7e−04
Hazard Ratio = 0.482





























BAALC: Validation Cohort: (n = 215)
p−value (log−rank one sided) = 0.0205
Hazard Ratio = 0.686





























EVI1: Training Cohort: (n = 147)
p−value (log−rank one sided) = 0.012
Hazard Ratio = 0.442





























EVI1: Validation Cohort: (n = 215)
p−value (log−rank one sided) = 0.004
Hazard Ratio = 0.44





























MN1: Training Cohort: (n = 147)
p−value (log−rank one sided) = 0.00045
Hazard Ratio = 0.456





























MN1: Validation Cohort: (n = 215)
p−value (log−rank one sided) = 0.2329
Hazard Ratio = 0.877
Figure 3 Kaplan-Meier analysis of overall survival (OS) for BAALC, EVI1 and MN1 in training (left) and validation cohorts (right).
Individual KM strata are color coded to depict favorable (F), intermediate (I), unfavorable (U) cytogenetic risk. The intermediate group is plotted in
grey because it was re-stratified into low expressors (blue) and high expressors (red). cutoff points used in this validation study are BAALC
expression −0.95 (derived from the 30th percentile in the training), EVI1 expression 0.987 (derived from a single short survival case in the training
cohort), MN1 expression −0.76 (derived from the 30th percentile in the training).
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age in years, gender, White Blood Cell count, percent of
blast cells in bone marrow and platelet count at diagnosis
(Table 4). When adjusting for these variables, EVI1
overexpression proved an independent significant prog-
nostic factor (p = 0.019; HR = 2.21; Table 4), but BAALC
expression levels not. Therefore we have also analyzed
the validation cohort after excluding all n = 12 EVI1
overexpression cases and demonstrate that low BAALC
expression level remains an independent prognosticfactor (p = 0.035; HR =0.62; Table 5) when evaluated in
all (n = 203) low EVI1 cases.
Conclusions
We have developed a standardized assay for BAALC
and EVI1 gene expression markers with prognostic
value for patients with AML. We trained an assay on a
well-characterized cohort of intermediate cytogenetic
risk AML cases and determined cutoff points for the
gene expression markers BAALC and EVI1. Similar to
Table 4 Multivariate analysis in the validation cohort for
OS using Cox Proportional Hazard model
Variable p-value HR 95% CI
BAALC 0.1 1.42 0.93–2.15
EVI1 0.019 2.21 1.14–4.27
CEBPA-dm 0.052 0.36 0.13–1.01
NPM1-ABD 0.21 0.76 0.50–1.17
FLT3-ITD 0.017 1.64 1.09–2.46
age in years (continuous variable, in yrs) 0.021 1.02 1.00–1.03
gender 0.76 1.06 0.73–1.55
White blood Cell Count at diagnosis
[×10^9/l]
0.17 1.00 1.00–1.00
Percentage of blast cells in bone marrow 0.45 1.00 0.99–1.00
Platelets at diagnosis [×10^9/l] 0.24 1.00 1.00–1.00
Gene expression, gene mutation and gender variables are binary, while age,
WBC, % blast, and platelets are continuous variables.
Table 2 Mutations at diagnosis stratified for BAALC









NPM1-ABD 85 49 36 <0.0001
CEBPA-dm 10 0 10 0.0146
FLT3-ITD 79 25 54 0.148
Table 5 Multivariate analysis in the validation cohort
excluding high EVI1 cases
Variable p-value HR 95% CI
BAALC-low 0.035 1.56 1.03–2.54
CEBPA-dm 0.047 0.35 0.12–0.98
NPM1-ABD 0.36 0.82 0.53–1.26
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was selected and validated to predict for worse OS in
AML patients. Low BAALC was trained as those cases
with the lowest 30th percentile BAALC expression level
and found to predict for significantly worse OS in an inde-
pendent cohort of intermediate cytogenetic risk cases
(Table 1). Both EVI1 overexpression and low BAALC ex-
pression levels were significantly associated with clinical
outcome as shown by multivariate analysis, including
other molecular markers such as NPM1, FLT3 and CEBPA
gene aberrations. Two other prognostic gene expression
markers, evaluated in this study, MN1 and ERG were
found not significantly prognostic in either training or
validation cohorts and therefore not added to the
AMLprofiler assay. We successfully standardized and vali-
dated OS prognostic assays for low BAALC and high EVI1
expression levels in AML that we integrated into an
in vitro diagnostic platform for clinical use that simultan-
eously detects t(8;21), t(15;17), inv(16), t(16;16), NPM1,
and CEBPA double mutations.
Methods
Patients and treatment
This study used three datasets, a training cohort, a veri-
fication cohort and a validation cohort. The training co-
hort consisted of 147 intermediate cytogenetic risk AML
cases, the validation cohort of 215 intermediate cytogen-
etic risk cases from the HOVON collaborative treatment
group (www.hovon.nl; studies HOVON-4, -29, -32, -42
and -43). All subjects provided written informed consent
in accordance with the Declaration of Helsinki. This re-
search has been approved by the Medical Ethical Com-
mittee of the Erasmus University Medical Center. The
verification cohort consisted of 242 cytogenetically nor-
mal AML cases and was publically available ([21],
GSE12417).Table 3 Mutations at diagnosis stratified for EVI1
expression levels in the validation cohort
Variable Total







NPM1-ABD 85 85 0 0.0039
CEBPA-dm 10 10 0 1
FLT3-ITD 79 77 2 0.218Measurements of BAALC, EVI1, ERG and MN1 expression
Training and validation expression levels are measured in
RNA extracted from ficoll purified blast cells from diag-
nostic BM and PB samples as previously described [22].
The stored hybridization cocktails have been re-hybridized
to the AMLprofiler custom GeneChip which has 995
probe sets that are a subset of the Affymetrix U133Plus2.0
GeneChip (n = 505 cases, GSE42194). We had previously
validated 10 re-hybridizations of cocktails including the
freeze-thaw cycles and could not show impact on mRNA
quantification (data not shown). Probe set intensity data
for the external cohort are obtained from the Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov/geo/; acces-
sion GSE12417) and copied from U133Plus2.0 format into
the corresponding 995 probe set coordinates of a dummy
AMLprofiler to guarantee standardized data analysis in-
cluding MAS5.0 summarization, chip normalization and
Geometric Mean Centering per probe set (gene). Next, the
expression level of BAALC is calculated as the average ofFLT3-ITD 0.038 1.56 1.02–2.39
age in years 0.012 1.02 1.00–1.04
gender 0.74 1.07 0.72–1.58
White blood Cell Count at diagnosis
[×10^9/l]
0.14 1.00 1.00–1.00
Percentage of blast cells in bone marrow 0.2 0.99 0.99–1.00
Platelets at diagnosis [×10^9/l] 0.28 1.00 1.00–1.00
Gene expression, gene mutation and gender variables are binary, while age,
WBC, % blast, and platelets are continuous variables.
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ance normalization. The expression level of ERG is the
average of probe sets 241926_s_at and 213541_s_at after
mean variance normalization and the expression level of
EVI1 is the average of probe sets 221884_at and 226420_at
after mean variance normalization. The expression level of
MN1 is the value of the probe set 205330_at.
Cutoff point development
Cutoff points for BAALC, ERG and MN1 expression levels
were developed using a 147 case training cohort of inter-
mediate cytogenetic risk AML as well as a 242 case normal
karyotype AML cohort with overall survival (OS) informa-
tion. Figure 1 then served to derive optimal cutoff points.
It shows results of 1000 random repetitions of cross-
validation in training and verification cohorts stratifying be-
tween 10–90th percentile expression levels in steps of 5%.
In each repetition the particular cohort is randomly split
into 50% train and 50% test cases. The results of the test
cases are used to calculate the logrank for OS between high
and low cases. The number of significant p-values (logrank
p < 0.05) during 1000 repetitions is plotted on the y-axis.
For each gene a cutoff point was chosen from the optimum
significance in the training set. As two peaks were observed
for BAALC the verification dataset (Figure 1, green bars)
guided the choice for the peak at the 30th percentile
(Figure 1). For MN1 the 30th percentile was the only
optimum and no clear significant peak was seen in the veri-
fication data. For ERG, there was no optimum in the train-
ing data, but only in the verification data. The cutoff points
for BAALC and MN1 were then translated from percentile
value to their corresponding expression levels. For BAALC
(−0.95) and for MN1 (−0.76). These expression levels were
locked-down for external significance testing in the valid-
ation data set. The cutoff point selection was different for
EVI1. Because the expression distribution is skewed to-
wards very low or no expression with just a few percent of
cases with high expression (Figure 2) the cutoff value was
chosen at 0.987 such that 12 cases are annotated as having
high EVI1 expression with significantly shorter OS.
Statistical analysis
Standardized methods for prognostic stratification of AML
patients with intermediate cytogenetic risk based on the
genes BAALC, ERG, MN1 and EVI1 are established by
selecting an appropriate cutoff point for each gene that
classifies patients into low- or high expressers. Because of
the extremely skewed distribution of EVI1 expression level,
the above CV procedure does not have enough power to
yield a meaningful result for EVI1 overexpression.
Assay validation
The cutoff points for the genes BAALC and EVI1 de-
rived from the training cohort were validated by meansof Kaplan-Meier analysis of low expressers (below cutoff
point) versus high expressers (above cutoff point). A
gene and cutoff point passes the validation if the one-
sided p-value with respect to difference in OS between
low expressers and high expressers according to the log-
rank test is statistically significant, i.e., p ≤ 0.05. A one-
sided p-value is justified because for each of the four
genes there is prior knowledge that a higher expression
predicts for worse OS prognosis.
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